Related Experiment Video
Updated: Jun 20, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Substrate competitive GSK-3 inhibitors - strategy and implications.
Hagit Eldar-Finkelman1, Avital Licht-Murava, Shmuel Pietrokovski
1Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. heldar@post.tau.ac.il
Biochimica Et Biophysica Acta
|September 23, 2009
Summary
Glycogen synthase kinase-3 (GSK-3) is linked to diseases like diabetes. New substrate-competitive inhibitors offer a more specific therapeutic approach than current ATP-competitive drugs.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Glycogen synthase kinase-3 (GSK-3) is a key protein kinase implicated in various diseases, including diabetes and neurological disorders.
- Elevated GSK-3 activity is a pathological hallmark, suggesting therapeutic potential for its inhibition.
- Current GSK-3 inhibitors primarily target ATP binding sites, often lacking specificity.
Purpose of the Study:
- To explore the development of novel, substrate-competitive inhibitors for Glycogen synthase kinase-3 (GSK-3).
- To enhance specificity and therapeutic utility by targeting substrate recognition mechanisms.
- To establish GSK-3 as a viable drug discovery target for related pathologies.
Main Methods:
- Utilized computational modeling to analyze GSK-3 substrate interactions.
- Employed biochemical assays to validate inhibitor efficacy and specificity.
- Conducted molecular analyses to understand enzyme-substrate recognition dynamics.
Main Results:
- Identified key insights into GSK-3's substrate recognition processes.
- Demonstrated the potential for developing highly specific inhibitors.
- Provided a strategic framework for substrate-competitive inhibitor design.
Conclusions:
- GSK-3 represents a promising target for drug development.
- Substrate-competitive inhibition offers a more specific therapeutic strategy.
- This approach holds potential for clinical applications in GSK-3-related disorders.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...